Table 2.

Percentage change in bone mineral density from baseline to 3 and 6 months.

	Group A		Group B		Group A vs Group B
	Mean % Change	P-value	Mean % Change	P-value	Mean % Change	P-value
LS
3 months	5.79 (1.43)	0.001∗	5.44 (0.85)	<0.001∗	0.34 (1.66)	0.836
6 months	9.75 (1.21)	<0.001∗	7.42 (1.36)	<0.001∗	2.33 (1.82)	0.213
FN
3 months	0.68 (1.13)	0.555	3.00 (1.09)	0.019∗	2.31 (1.57)	0.153
6 months	2.36 (1.18)	0.068	1.64 (1.32)	0.240	0.72 (1.77)	0.689
TH
3 months	2.12 (0.34)	<0.001∗	1.67 (1.16)	0.178	0.45 (1.21)	0.715
6 months	2.43 (0.78)	0.008∗	2.07 (1.21)	0.115	0.36 (1.44)	0.806

FN, femoral neck; TH, total hip; LS, lumbar spine.

Group A: romosozumab plus denosumab; Group B: teriparatide plus denosumab.

Results are derived from linear mixed‐effects models with a random intercept for each subject. Values are expressed in least-squares means (standard error) as the percent change from baseline.

∗P < 0.05.